Lantheus and POINT Biopharma Announce Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).